The reiteration of a Buy rating and maintenance of a $17 price target by a reputable analyst like Joon Lee from Truist Securities could positively influence investor sentiment towards WAVE Life Sciences. This endorsement suggests a strong belief in the company's potential for growth and value, likely encouraging both current and potential investors.